A Study of Olaparib and Cediranib in Ovarian Cancer

Video

Christina M. Annunziata, MD, PhD, head, Translational Genomics Section, National Cancer Institute, discusses the phase II/III study of olaparib (Lynparza) and cediranib for patients with platinum-resistant ovarian cancer.

Recent Videos
Related Content